pre-IPO PHARMA

COMPANY OVERVIEW

Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals such as Nature Medicine (doi:10.1038/nm.4132) and Nature Metabolism (doi: 10.1038/s42255-019-0073-4). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


May 11, 2021

Amazentis Pioneers First Sports Nutrition Program with Mitopure™ (Urolithin A)


Jul 27, 2020

Amazentis Launches Timeline™ powered by Mitopure™ A Breakthrough in Cellular Nutrition


Jan 23, 2020

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos


Jun 14, 2019

First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, PUblished by Amazentis and Researchers From the EPFL and SIB


Apr 2, 2019

Nestlé Health Science invests in global strategic partnership with Amazentis to develop its new cellular nutrient Urolithin A


For More Press Releases


Google Analytics Alternative